Chronic obstructive pulmonary disease in Poland: distribution of patients according to the new GOLD 2011 classification. Cross-sectional survey by Wesołowski, Stefan et al.
www.pneumonologia.viamedica.pl
PRACA ORYGINALNA
511
Address for correspondence: Prof. Stefan Wesołowski, Department of Respiratory Physiopathology, National Tuberculosis and Lung Diseases Research Institute, Płocka 26, 
01–138 Warsaw, tel.: 22 431 22 23, e-mail: s.wesolowski@igichp.edu.pl 
DOI: 10.5603/PiAP.2014.0068
Praca wpłynęła do Redakcji: 3.06.2014 r.
Copyright © 2014 PTChP
ISSN 0867–7077
Stefan Wesołowski1, Piotr W. Boros1, Tomasz Dębowski2
1Department of Respiratory Physiopathology, National Tuberculosis and Lung Diseases Research Institute, Warsaw
Head: Prof. S. Wesołowski, MD, PhD
2Medical Division, Chiesi Poland, Warsaw 
Head: T. Dębowski
Chronic obstructive pulmonary disease in Poland: distribution  
of patients according to the new GOLD 2011 classification.  
Cross-sectional survey
Przewlekła obturacyjna choroba płuc w Polsce: podział pacjentów według nowej 
klasyfikacji GOLD 2011. Badanie przekrojowe
The research was supported by Chiesi Poland (printing the materials, collecting data, and database processing)
Abstract
Introduction: In 2011 new classification for chronic obstructive pulmonary disease (COPD) was introduced, which are not based 
on the extent of airflow limitation alone, but also on symptoms and risk of exacerbation. The objective of our work was to present 
the characteristics of COPD patients according to the GOLD 2011 categories.
Material and methods: A cross-sectional survey was performed with the participation of 411 specialists in pneumonology or 
allergology all over from Poland.
Results: In the group of 2271 patients we obtained the following distribution of COPD categories: A 687 (30.3%), B 403 (17.7%), 
C 256 (11.3%), and D 925 (40.7%). There were very few patients with no exacerbation (1.3%). In subgroups A and B there were 
no such patients at all. The main reason for classification of patients into categories C and D was the number of exacerbations 
of COPD (66.0% and 40%, respectively). Cardiovascular comorbidities were more frequent in subgroups B and D, with more 
symptoms (82%) than in subgroups A and C (57%, p < 0.001).
Conclusions: In a large group of patients, representative of the population of COPD patients in Poland, we observed an uneven 
distribution of patients in the GOLD 2011 categories, with 71% of patients assigned to category A or D. In our study, the main 
reason for classifying to category C or D was the high risk of disease exacerbation rather than the degree of FEV1 reduction, as 
noted in other reports.
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Streszczenie
Wprowadzenie: W 2011 roku została wprowadzona nowa klasyfikacja przewlekłej obturacyjnej choroby płuc (POChP), uwzględ-
niająca nie tylko stopień obturacji oskrzeli, ale także nasilenie objawów i ryzyko zaostrzeń choroby. Celem niniejszej pracy było 
przedstawienie charakterystyki pacjentów z POChP zgodnie z kategoriami GOLD 2011.
Materiał i metody: Przeprowadzono badanie przekrojowe z udziałem 411 lekarzy specjalistów pneumonologii i alergologii z całej 
Polski.
Wyniki: W grupie 2271 chorych stwierdzono następujący rozkład pacjentów w poszczególnych kategoriach POChP: A 687 
(30,3%), B 403 (17,7%), C 256 (11,3%) i D 925 (40,7%). W całej grupie było bardzo mało pacjentów bez zaostrzeń POChP (1,3%), 
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a w podgrupach A i B takich pacjentów nie było wcale. Głównym powodem kwalifikacji do kategorii C i D była liczba zaostrzeń 
POChP (odpowiednio 66,0% i 40% pacjentów). Współistnienie chorób układu krążenia stwierdzano częściej w podgrupach 
o nasilonych objawach B i D (82%) niż w podgrupach A i C (57%, p < 0,001).
Wnioski: W dużej grupie pacjentów, reprezentatywnej dla populacji chorych na POChP w Polsce, wykazano nierównomierny 
rozkład chorych w poszczególnych kategoriach klasyfikacji GOLD 2011. Najliczniejsze były podgrupy A i D, do których zaliczono 
71% wszystkich chorych. W niniejszym badaniu główną przyczyną klasyfikacji do kategorii C lub D było wysokie ryzyko zaostrzeń 
choroby, a nie — jak stwierdzano w innych doniesieniach — stopień zmniejszenia FEV1.
Słowa kluczowe: POChP, klasyfikacja GOLD 2011, zaostrzenia POChP
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is usually a progressive, complex dise-
ase leading to considerable reduction in quality 
of life, due to respiratory disability, and finally 
to death. In Poland COPD is diagnosed in more 
than 20% of smokers aged over 40 years [1]. 
COPD is already a serious burden on health care 
systems in many countries, and the burden is set 
to increase: by 2020 COPD is estimated to become 
the world’s third major cause of death [2]. The 
establishment of the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) was the reac-
tion to the challenges posed by COPD. On the 
basis of reliable clinical trials, recommendations 
have been formulated for diagnosing and treating 
COPD, which are available around the world. The 
first document, published more than 10 years 
ago [3], has been updated many times. In 2011 
new classification of the disease was introduced, 
which caused a major change in the approach to 
COPD [4]. In the recommendations thus far the 
severity of the disease was defined only on the 
basis of the degree of FEV1 reduction measured 
by spirometry. The new assessment scheme is 
the first multidimensional system that takes 
into account not only the results of spirometry, 
but also the intensity of symptoms and the risk 
of disease exacerbation. The new classification 
system assigns patients to one of the following 
four categories: A — scant symptoms, fairly 
good lung function, low risk of exacerbations; 
B — more symptoms, fairly good lung function, 
low risk of exacerbations; C — scant symptoms, 
poor lung function or high risk of exacerbations; 
and D — more symptoms, poor lung function or 
high risk of exacerbations. The introduction of 
the GOLD 2011 recommendations encouraged 
renewed assessment of the distribution of patients 
in particular categories according to the new 
classification. Since the new classification a few 
studies have been published with the application 
of the GOLD 2011 assessment system among the 
pre-established groups of patients [5–8]. These 
analyses gave new information on the distribu-
tion and characteristics of COPD patients, but 
originally these were clinical or epidemiological 
studies, and their protocols did not contain ob-
jectives, to which have now been applied. Only 
a few studies have evaluated the characteristics 
of patients with COPD according to GOLD 2011 
classification in groups of patients not selected for 
clinical trials [9, 10]. In Poland, little research has 
been done on the epidemiology of COPD [1, 11], 
and so far there has been no work referring to 
the GOLD 2011 classification. The objective of 
our work was to present the characteristics of 
patients with COPD encountered in daily medical 
practice, taking into account the new GOLD 2011 
categorisation system, and its comparison with 
the previous GOLD 2007 classification. 
Material and methods
We conducted a multicentre, non-interven-
tional, observational survey aimed at assessing 
patients with COPD. The data were collected for 
three months, from February to April 2013. A total 
of 411 doctors, specialists in pneumonology or 
allergology, from all over Poland, who were taking 
care of the patients with COPD, were involved in 
the study. In order to ensure an even inclusion of 
patients from various centres, each doctor could 
qualify no more than ten patients for the study. 
The including criteria were as follows: COPD 
diagnosed at least six months earlier and confir-
med by spirometry, age ≥ 40 years, regular intake 
of inhaled long-acting beta2-agonists (LABA), or 
temporary intake of short-acting beta2-agonists. 
The exclusion criteria were as follows: asthma in 
the patient history, exacerbation of COPD within 
the past six weeks, actual participation in any 
other clinical trial, or the coexistence of a chronic 
disease in an unstable condition. Only outpatients 
were included. The doctors participating in the 
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study completed questionnaires including the 
following items: age, sex, duration of COPD, smo-
king history, modified Medical Research Council 
dyspnoea score (mMRC) [12], number of exacer-
bations within the past 12 months, last measured 
FEV1/FVC and FEV1 percentage of predicted, and 
the presence and type of comorbidities. An exa-
cerbation of COPD was defined as a worsening 
of symptoms that required oral corticosteroids 
and/or antibiotics, and/or hospitalisation. On 
the basis of the data from the questionnaires, we 
were able to assign the patients to proper GOLD 
2011 A, B, C, or D category. Category A included 
patients with mMRC below 2 and FEV1 equal to 
or higher than 50% of the predicted, and with 
less than two COPD exacerbations within a year. 
Category B included the patients with mMRC 
score two or more and FEV1 equal to or higher 
than 50% of predicted, and less than two COPD 
exacerbations in a year. Category C included 
patients with mMRC below 2 and at least one of 
the following conditions met: FEV1 below 50% 
of the predicted or at least two exacerbations of 
COPD in a year. Category D included the patients 
with mMRC of 2 or more and at least one of the 
following conditions met: FEV1 below 50% of the 
predicted or at least two exacerbations of COPD 
in a year. 
Consent was obtained from each doctor involved 
in the study. Ethics approval was not required for 
this study as no patient-identifiable material was 
recorded; all collected data were anonymous. 
Statistical methods
Summary statistics included the mean ± 
standard deviation for continuous data and num-
ber (percentage) for categorical data. The chi-squ-
ared test was used to check the interdependence 
between the categorical data. The verification of 
differences between the groups, for more than two 
groups, was conducted with one-way analysis of 
variance. Data were entered into Statistica softwa-
re, version 9.1 (StatSoft, Inc. 2010) for analyses. 
Results
From among the collected 4110 questionna-
ires, the data relating to the spirometry values, 
the number of disease exacerbations, and the 
intensity of symptoms was available for 2271 
(55.3%) of the patients in the stable period of the 
disease, who fulfilled the spirometry-based crite-
ria for COPD diagnosis (FEV1/FVC < 0.7). Further 
calculations are related to these patients (n = 
2271 constitutes 100%). There were 1457 (64.2%) 
men and 814 (35.8%) women, and the average age 
was 63.5 ± 9.8 years. Active or former smokers 
comprised 91.9% of the study group, and mean 
tobacco exposure was 31.8 ± 18.1 pack-years. 
Mean FEV1 was 58.6 ± 15.0% of predicted. The 
figures relating to the patient characteristics are 
presented in Table 1. 
The following distribution was obtained for 
the analysed group: category A, 687 (30.3%); cate-
gory B, 403 (17.7%); category C, 256 (11.3%); and 
category D, 925 (40.7%). The graphic presentation 
of the GOLD 2011 category distribution is shown 
in Figure 1.
Analysis of the subgroups according to the 
ABCD categorisation showed statistically signi-
ficant differences between them with regards to 
age, exposure to tobacco smoke, and, understan-
dably, with regards to the frequency of exacerba-
Table 1. Patient characteristics by category: A, B, C, and D, according to GOLD 2011
Categories of chronic obstructive pulmonary disease
A 
(n = 687)
B 
(n = 403)
C 
(n = 256)
D 
(n = 925)
Total (n = 2271)
Age 59.6 ± 9.3 65.6 ± 8.5 60.6 ± 9.8 66.3 ± 9.3 63.5 ± 9.7
Sex (f/m) 37%/63% 36%/64% 38%/62% 34%/66% 36%/64%
BMI [kg/m2] 26.66 ± 3.94 27.65 ± 4.52 26.88 ± 4.4 27.06 ± 4.81 27.02 ± 4.47
Smoking (never/past/active smokers) 8%/43%/49% 8%/49%/43% 11%/46%/43% 6%/52%/42% 7%/48%/44%
Pack years 26.8 ± 16.8 32.7 ± 15.9 28.6 ± 16.2 35.8 ± 19.1 31.8 ± 18.0
FEV1% pred. 69.3 ± 10.1 63.3 ± 8.5 58.0 ± 13.3 48.5 ± 12.7 58.5 ± 14.4
Exacerbations/year 1.00 ± 0.00 1.00 ± 0.00 1.97 ± 0.69 2.00 ± 0.80 1.52 ± 0.75
mMRC 1.76 ± 0.42 3.13 ± 0.37 1.91 ± 0.29 3.43 ± 0.6 2.7 ± 0.91
BMI — body mass index; mMRC — modified Medical Research Council dyspnoea score mMRC — modified Medical Research Council dyspnoea score 
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group only 30 (1.3%) patients (all of them from 
categories C or D) did not have any exacerbations 
in the previous 12 months. 
We compared the distribution of the patients 
in the new assessment system with reference to 
the previous GOLD 2007 classification, which was 
applied until 2010. In GOLD 2007 the severity of 
COPD was assessed by the reduction in FEV1% of 
predicted (1 mild FEV1 ≥ 80%, 2 moderate 50% ≤ 
FEV1 < 80%, 3 severe 30% ≤ FEV1 < 50%, 4 very 
severe FEV1 < 30%). Graphical presentation of 
the results is shown in Figure 2. 
The patients who were previously classified 
as moderate COPD are now present in all catego-
ries of the new assessment system. They are the 
most numerous in categories A, B, and C, but also 
constitute a significant part of category D. The pa-
tients with severe and very severe COPD are now 
assigned mainly to category D and partly to C. 
In the GOLD 2011 classification, categories A 
and B are explicitly defined. This is not the case 
in case of categories C and D. Into category C we 
can include the patients with mMRC below 2 and 
FEV1 below 50% of the predicted value or with 
high risk of exacerbations (at least 2 exacerbations 
in the last year), as well as patients who fulfil 
both of these criteria. Respectively, in category 
D we can find patients with mMRC of 2 or more 
and FEV1 below 50% of predicted value or with 
high risk of exacerbations, as well as the patients 
Figure 1. Proportions of patients in each GOLD 2011 COPD category 
in the study population
Figure 2. Distribution of COPD patients according to the GOLD 2007 and the new GOLD 2011 classification
tions and intensity of symptoms as well as the 
severity of airway obstruction. The patients with 
intense symptoms (categories B and D) were older 
and smoked more cigarettes than patients from 
categories A and C (ANOVA, p < 0.001). What 
is noteworthy is the fact that among the patients 
assigned to categories A and B there were no pa-
tients without an exacerbation. In the whole study 
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fulfilling both these conditions (low FEV1 and 
high risk of exacerbations).
We analysed the particular reasons for as-
signing patients to category C or D. Among the 
patients in category C, in the majority of them 
(66.0%) the number of exacerbations was the 
only reason for classification, while only one 
out of four patients (23.8%) was assigned to this 
category on the basis of airway obstruction se-
verity. The consistency of the spirometry results 
and the history of exacerbations, i.e. fulfilling 
both conditions for category C, was observed 
in 10.2% of cases. Respectively, in category D, 
40.1% patients were assigned exclusively on 
the basis of the number of exacerbations, 25.8% 
of the patients were classified due to the airway 
obstruction severity, and 34.1% due to having 
fulfilled both conditions. A graphical presenta-
tion is shown in Figure 3.
The potential impact of cardiovascular dise-
ases on the symptomatic form of the disease was 
also assessed. In 82% of patients who reported 
more symptoms (categories B and D), cardio-
vascular comorbidities (arterial hypertension, 
ischaemic heart disease, cardiac failure, or atrial 
fibrillation) were found. In subgroups A and C, 
with fewer symptoms, such a coincidence was 
observed in 57% of cases (p < 0.001) (numerical 
data shown in Fig. 4).
Discussion
GOLD 2011 recommendations have intro-
duced a new, multidimensional system for ca-
tegorising patients with COPD, aimed at a more 
extensive assessment of the disease severity and 
a more adequate, better suited choice of treatment. 
The recommendations were mainly based on the 
experts’ opinions issued on the basis of clinical 
trials in large groups of patients with COPD, inc-
luded in three major projects: TORCH, UPLIFT, 
and ECLIPSE [13–15]. Thus, they needed to be 
tested in general populations of patients. Our 
study is the first to describe the distribution of 
COPD patients in chest diseases specialist cen-
tres throughout Poland according to GOLD 2011 
classification. As in other studies on patients 
with previously diagnosed COPD, we observed 
that the most highly populated categories were 
A and D, including a total of 71% of the patients. 
Such a pattern of distribution was reported in 
patient groups qualified for clinical trials, and 
in primary care as well [7, 10, 16]. Compared 
with the primary-care from report Haughney et 
al. [10], we found an even greater proportion of 
patients at high risk of unfavourable course of 
the disease — subgroups C and D (52% v. 36%, 
respectively). It is easy to understand that the 
patients with more symptoms, frequent exacer-
bations and poor lung function are often refer-
red to chest disease or allergology specialists. 
However, it was surprising that our subgroup A 
had so many patients, as they represented the 
mildest form of the disease, which does not need 
specialist care. In categories A and B there were 
no patients without any exacerbations in the 
last 12 months, so it is likely that the patients 
with preserved lung function have to experien-
ce exacerbations to consider the diagnosis of 
COPD justified. This also means that screening 
spirometry programs aimed at early detection 
of COPD are ineffective, and COPD in subjects 
Figure 3. Proportions of the patients classified into category C or D of 
COPD on the basis of spirometry (FEV1 < 50% of predicted) and/or the 
history of exacerbations
Figure 4. The incidence of cardiovascular comorbidities in the sympto-
matic subgroups B and D (mMRC ≥ 2) and subgroups with fewer symp-
toms A and C (mMRC < 2) of chronic obstructive pulmonary disease
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with mild or moderate airway obstruction and 
no exacerbations is underdiagnosed. 
By including factors other than FEV1 in 
the assessment, the new system has resulted in 
a redistribution of patients into specific categories 
of the disease as compared to the GOLD 2007 
classification. This is particularly related to the 
group of moderate COPD, which was previo-
usly the most numerous according to the GOLD 
2007 assessment system. Now these patients 
are distributed among all categories of the new 
system, ranging from the mildest category, A, to 
the most severe, D. The GOLD 2011 classification 
has resulted in a large category D, which includes 
patients with moderate and severe as well as very 
severe COPD, according to the previous GOLD 
2007 classification. This change of distribution 
pattern has direct consequences for treatment 
because particular ABCD categories have their as-
signed relevant treatment schemes. The new way 
of classifying patients has increased the number 
of patients for whom a more intensive therapy is 
recommended, with the use of inhaled cortico-
steroids as maintenance treatment. According to 
the previous GOLD 2010 recommendations, the 
patients with moderate form of COPD did not 
have indications for regular intake of inhaled cor-
ticosteroids, while the recommended treatment 
for them was the long-acting beta2-agonists or 
long-acting anticholinergics only. The GOLD 2011 
recommendations indicated the use of inhaled 
corticosteroids for patients in categories C and D, 
which comprises a significant part of patients 
with GOLD 2007 moderate COPD, who have now 
been shifted to these categories.
The characteristics of our patients were simi-
lar to those shown by Lange et al. [8]. Patients 
in subgroups B and D, i.e. those with intense 
symptoms, were older and had higher incidence 
of cardiovascular comorbidities as compared to 
subgroups A and C. Ischaemic heart disease and 
cardiac failure may cause a reduction in exerci-
se capacity, just as COPD does. We believe that 
cardiovascular comorbidities may contribute to 
considerable intensification of symptoms among 
patients in categories B and D. Agusti et al. [7] 
observed worse exercise capacity and higher con-
centration of inflammatory biomarkers in such pa-
tients, compared to those from the two remaining 
categories, A and C. The most significant differen-
ces between our group of patients and the groups 
from other reports were found in the analysis of 
reasons for classification into categories C and D. 
In our patients the main reason for assignment to 
one of these subgroups was high risk of exacerba-
tions, assessed on the basis of the history of the 
disease so far (categories C, 66% and D, 40%, of 
the patients). The results of previously published 
studies showed a reduction of FEV1 as the basic 
reason for inclusion into category C (70–78% of 
the patients) or D (63–79% of the patients) [6, 7]. 
In our group there were more patients with 
frequent exacerbations of COPD (39% of the 
whole analysed group, including 76% patients 
in category C and 74.2% patients in category D) 
than in the groups of patients qualified for clini-
cal trials. In the ECLIPSE study [7], the patients 
with frequent exacerbations constituted 28% of 
patients in subgroup C and 27% of patients in 
subgroup D. We do not have any clear explanation 
of such differences. We can speculate that on the 
one hand, patients with frequent exacerbations 
may be reluctantly included in clinical trials due 
to a greater risk of their withdrawal from the stu-
dy. On the other hand, doctors in general practice 
may diagnose exacerbations of the disease too 
readily. We think it is likely that even trivial re-
spiratory infections, often unnecessarily treated 
with antibiotics, constitute a sufficient reason to 
diagnose an exacerbation of COPD. This could 
explain the very low number of patients without 
any exacerbations in the whole our group, as well 
as their total absence in categories A and B. 
Strengths and weaknesses of the study
One strength of our research is the large 
number of patients from all over Poland, without 
the selection conditions typical of clinical tests, 
which usually qualify only a few percent of the 
patient population. Besides the basic criteria for 
diagnosing COPD, we did not impose any other 
limitations on including patients in the stable pe-
riod of the disease. We may consider that we have 
selected a group representative of the population 
of patients with COPD, treated as outpatients in 
specialist centres. 
Our study also has some weaknesses. The 
sponsor of the study decided not to include pa-
tients receiving regular treatment with SAMA/
LAMA. It is difficult to assess the impact of this 
decision on the results of the study. In the qu-
estionnaire we only used the mMRC score for 
assessing the symptoms; we did not use the COPD 
Assessment Test (CAT). We did this on purpose to 
maintain the simplicity of the questionnaire. The 
CAT is not commonly used in Poland as yet, and 
its completion could have caused problems for 
patients and doctors who were not familiar with 
the test. We realise that the mMRC score assesses 
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only one aspect of the symptoms of COPD, i.e. 
dyspnoea, whereas the CAT is a multidimensional 
tool. The results of the assessment of symptoms, 
and in turn the classification of patients into 
proper GOLD 2011 categories with the use of 
mMRC score and the CAT, may therefore differ. 
We have not verified the correctness of diagnosing 
exacerbations of COPD either, leaving this to the 
competence of the doctors completing the qu-
estionnaires. In order to facilitate the completion 
of this point, we included criteria for diagnosing 
mild, moderate, and severe exacerbation of the 
disease in the questionnaire. The frequency of 
diagnosed exacerbations may not reflect their 
actual frequency in the analysed population; but 
still our results show the real diagnostic habits of 
the doctors completing the survey. 
Conclusions
In a large group of patients, representative of 
the population of patients with COPD in Poland, 
we observed an uneven distribution of patients 
in GOLD 2011 categories, with the majority of 
patients belonging to the mildest category A or 
the most severe category D. In the whole of our 
population there were very few patients with no 
exacerbations of COPD. In subgroups A and B 
all patients experienced exacerbations, which 
we believe could contribute to the diagnosis of 
COPD. In our patients, the main reason for classi-
fying patients into category C or D was high risk 
of disease exacerbation, rather that the degree of 
FEV1 reduction, as was observed in other studies.
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